359 related articles for article (PubMed ID: 19416980)
21. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer.
Smith J; Tho LM; Xu N; Gillespie DA
Adv Cancer Res; 2010; 108():73-112. PubMed ID: 21034966
[TBL] [Abstract][Full Text] [Related]
22. Mitotic DNA damage response: Polo-like kinase-1 is dephosphorylated through ATM-Chk1 pathway.
Lee HJ; Hwang HI; Jang YJ
Cell Cycle; 2010 Jun; 9(12):2389-98. PubMed ID: 20581453
[TBL] [Abstract][Full Text] [Related]
23. Ultrasound activates ataxia telangiectasia mutated- and rad3-related (ATR)-checkpoint kinase 1 (Chk1) pathway in human leukemia Jurkat cells.
Furusawa Y; Iizumi T; Fujiwara Y; Hassan MA; Tabuchi Y; Nomura T; Kondo T
Ultrason Sonochem; 2012 Nov; 19(6):1246-51. PubMed ID: 22571845
[TBL] [Abstract][Full Text] [Related]
24. Roles of Kruppel-associated Box (KRAB)-associated Co-repressor KAP1 Ser-473 Phosphorylation in DNA Damage Response.
Hu C; Zhang S; Gao X; Gao X; Xu X; Lv Y; Zhang Y; Zhu Z; Zhang C; Li Q; Wong J; Cui Y; Zhang W; Ma L; Wang C
J Biol Chem; 2012 Jun; 287(23):18937-52. PubMed ID: 22496453
[TBL] [Abstract][Full Text] [Related]
25. ATR and Chk1 suppress a caspase-3-dependent apoptotic response following DNA replication stress.
Myers K; Gagou ME; Zuazua-Villar P; Rodriguez R; Meuth M
PLoS Genet; 2009 Jan; 5(1):e1000324. PubMed ID: 19119425
[TBL] [Abstract][Full Text] [Related]
26. ATR-Chk2 signaling in p53 activation and DNA damage response during cisplatin-induced apoptosis.
Pabla N; Huang S; Mi QS; Daniel R; Dong Z
J Biol Chem; 2008 Mar; 283(10):6572-83. PubMed ID: 18162465
[TBL] [Abstract][Full Text] [Related]
27. The role of checkpoint kinase 1 in sensitivity to topoisomerase I poisons.
Flatten K; Dai NT; Vroman BT; Loegering D; Erlichman C; Karnitz LM; Kaufmann SH
J Biol Chem; 2005 Apr; 280(14):14349-55. PubMed ID: 15699047
[TBL] [Abstract][Full Text] [Related]
28. The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors.
Goss KL; Koppenhafer SL; Waters T; Terry WW; Wen KK; Wu M; Ostergaard J; Gordon PM; Gordon DJ
Oncogene; 2021 Jan; 40(3):564-577. PubMed ID: 33191406
[TBL] [Abstract][Full Text] [Related]
29. P53 suppresses ribonucleotide reductase via inhibiting mTORC1.
He Z; Hu X; Liu W; Dorrance A; Garzon R; Houghton PJ; Shen C
Oncotarget; 2017 Jun; 8(25):41422-41431. PubMed ID: 28507282
[TBL] [Abstract][Full Text] [Related]
30. The topoisomerase I poison camptothecin generates a Chk1-dependent DNA damage checkpoint signal in fission yeast.
Wan S; Capasso H; Walworth NC
Yeast; 1999 Jul; 15(10A):821-8. PubMed ID: 10407262
[TBL] [Abstract][Full Text] [Related]
31. DNA methylation inhibitor 5-Aza-2'-deoxycytidine induces reversible genome-wide DNA damage that is distinctly influenced by DNA methyltransferases 1 and 3B.
Palii SS; Van Emburgh BO; Sankpal UT; Brown KD; Robertson KD
Mol Cell Biol; 2008 Jan; 28(2):752-71. PubMed ID: 17991895
[TBL] [Abstract][Full Text] [Related]
32. Cep164 is a mediator protein required for the maintenance of genomic stability through modulation of MDC1, RPA, and CHK1.
Sivasubramaniam S; Sun X; Pan YR; Wang S; Lee EY
Genes Dev; 2008 Mar; 22(5):587-600. PubMed ID: 18283122
[TBL] [Abstract][Full Text] [Related]
33. Suppression of Tousled-like kinase activity after DNA damage or replication block requires ATM, NBS1 and Chk1.
Krause DR; Jonnalagadda JC; Gatei MH; Sillje HH; Zhou BB; Nigg EA; Khanna K
Oncogene; 2003 Sep; 22(38):5927-37. PubMed ID: 12955071
[TBL] [Abstract][Full Text] [Related]
34. Revised genetic requirements for the decatenation G2 checkpoint: the role of ATM.
Bower JJ; Zhou Y; Zhou T; Simpson DA; Arlander SJ; Paules RS; Cordeiro-Stone M; Kaufmann WK
Cell Cycle; 2010 Apr; 9(8):1617-28. PubMed ID: 20372057
[TBL] [Abstract][Full Text] [Related]
35. Role of ATM and the damage response mediator proteins 53BP1 and MDC1 in the maintenance of G(2)/M checkpoint arrest.
Shibata A; Barton O; Noon AT; Dahm K; Deckbar D; Goodarzi AA; Löbrich M; Jeggo PA
Mol Cell Biol; 2010 Jul; 30(13):3371-83. PubMed ID: 20421415
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of ATR-dependent feedback activation of Chk1 sensitises cancer cells to Chk1 inhibitor monotherapy.
Massey AJ
Cancer Lett; 2016 Dec; 383(1):41-52. PubMed ID: 27693461
[TBL] [Abstract][Full Text] [Related]
37. Topoisomerase poisons differentially activate DNA damage checkpoints through ataxia-telangiectasia mutated-dependent and -independent mechanisms.
Siu WY; Lau A; Arooz T; Chow JP; Ho HT; Poon RY
Mol Cancer Ther; 2004 May; 3(5):621-32. PubMed ID: 15141020
[TBL] [Abstract][Full Text] [Related]
38. Requirement of MTA1 in ATR-mediated DNA damage checkpoint function.
Li DQ; Ohshiro K; Khan MN; Kumar R
J Biol Chem; 2010 Jun; 285(26):19802-12. PubMed ID: 20427275
[TBL] [Abstract][Full Text] [Related]
39. Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.
Bennett CN; Tomlinson CC; Michalowski AM; Chu IM; Luger D; Mittereder LR; Aprelikova O; Shou J; Piwinica-Worms H; Caplen NJ; Hollingshead MG; Green JE
Breast Cancer Res; 2012 Jul; 14(4):R109. PubMed ID: 22812567
[TBL] [Abstract][Full Text] [Related]
40. A MYBL2 complex for RRM2 transactivation and the synthetic effect of MYBL2 knockdown with WEE1 inhibition against colorectal cancer.
Liu Q; Guo L; Qi H; Lou M; Wang R; Hai B; Xu K; Zhu L; Ding Y; Li C; Xie L; Shen J; Xiang X; Shao J
Cell Death Dis; 2021 Jul; 12(7):683. PubMed ID: 34234118
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
